Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug ...
To say that 2seventy bio’s short two years of existence have been dramatic is an understatement. CEO Chip Baird told BioSpace transparency and a committed staff have kept the biotech going through ...
Eli Lilly will invest $4.5 billion to create the Lilly Medicine Foundry, which the drug giant says will be the first-ever ...
It took GLP-1 medications like Ozempic just seven years to surpass insulin as the the second most common treatment for type 2 ...
KUWAIT CITY, KUWAIT - Media OutReach Newswire - 2 October 2024 – Novo Nordisk Gulf, a leading global healthcare company, has been recognized as one of the Best Places ...
As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...
Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.
Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer’s disease, ALS and other brain diseases, CEO David Ricks said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback